SEC Form 4Coverage since May 26, 2026
$ASND insider trading
Over the last 12 months, Ascendis Pharma A/S insiders reported 6 buys totaling $237K and no sales across SEC Form 4 filings.
- Bought · 12m
- $237K 6 events
- Sold · 12m
- — 0 events
- Events · 12m
- 6 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $ASND · 12Mvia TradingView
Top insiders · 12m
BIENAIME JEAN JACQUES—4× · $159K
SMITH SCOTT THOMASEVP & Chief Financial Officer2× · $78K
All insider trades
6 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | SMITH SCOTT THOMASEVP & Chief Financial Officer · O | ▲ Buy | 100 | $219 | $22K | +2.3% | — |
| May 29, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 100 | $223.5 | $22K | +12.5% | — |
| May 29, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 200 | $222.3 | $44K | +33.3% | — |
| May 29, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 200 | $223.76 | $45K | +50% | — |
| May 29, 2026 | SMITH SCOTT THOMASEVP & Chief Financial Officer · O | ▲ Buy | 250 | $223.32 | $56K | +6.2% | — |
| May 26, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 200 | $236.24 | $47K | — | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ASND feed.